Roxadex6 mg

Roxadex is a potent, long-acting synthetic corticosteroid (glucocorticoid) with minimal mineralocorticoid activity. It is used systemically (oral or injectable) and locally (ophthalmic, otic, topical, intra-articular) for a wide range of conditions. Indications are classified below by strength of evidence.

Established/FDA-approved uses

• Endocrine disorders — adjunctive therapy in primary or secondary adrenocortical insufficiency (usually with a mineralocorticoid), congenital adrenal hyperplasia, non-suppurative thyroiditis, hypercalcemia associated with cancer
• Rheumatic disorders — adjunctive therapy in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, acute gouty arthritis, acute rheumatic carditis, systemic lupus erythematosus, dermatomyositis
• Allergic states — control of severe allergic conditions such as seasonal or perennial allergic rhinitis, drug hypersensitivity reactions, serum sickness, contact dermatitis, and severe anaphylactic reactions (as an adjunct after epinephrine)
• Dermatologic diseases — pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, severe psoriasis, severe seborrheic dermatitis
• Respiratory diseases — symptomatic sarcoidosis, berylliosis, fulminating or disseminated pulmonary tuberculosis (with appropriate anti-tuberculous therapy), aspiration pneumonitis
• Hematologic disorders — acquired autoimmune hemolytic anemia, immune thrombocytopenia (ITP), erythroblastopenia
• Neoplastic diseases — palliative management of leukemias and lymphomas; supportive care in solid tumor chemotherapy
• Nervous system — cerebral edema associated with brain tumor, neurosurgery, or head injury
• Edematous states — nephrotic syndrome without uremia (idiopathic or due to lupus erythematosus)
• Gastrointestinal diseases — to help patients through a critical period of ulcerative colitis and Crohn’s disease
• Ophthalmic diseases — severe acute and chronic allergic and inflammatory processes involving the eye (as ophthalmic preparations)
• Antiemetic — prevention of chemotherapy-induced nausea and vomiting, often used in combination with other antiemetics
• Diagnostic use — the Roxadex suppression test for evaluating hypothalamic-pituitary-adrenal axis function/Cushing’s syndrome

Guideline-supported / specific clinical uses

• COVID-19 — in hospitalized patients requiring supplemental oxygen or mechanical ventilation, per WHO and national treatment guidelines
• Croup (laryngotracheobronchitis) in children — single dose to reduce airway inflammation and severity of symptoms
• Bacterial meningitis — adjunctive therapy (given before or with the first antibiotic dose) in infants and children with Haemophilus influenzae type b meningitis, to reduce the risk of hearing loss and neurological sequelae
• Antenatal corticosteroid therapy — administered to the mother to accelerate fetal lung maturation when preterm delivery is anticipated (used under specialist obstetric supervision)
• High-altitude cerebral edema — treatment and prevention as an adjunct to descent

Use of Roxadex should always be guided and monitored by a qualified physician, with the lowest effective dose used for the shortest duration consistent with the condition being treated.

Each Dexamethasone tablet/oral solution contains dexamethasone (as base) as the active ingredient. Injectable preparations typically contain dexamethasone sodium phosphate (equivalent to a stated amount of dexamethasone phosphate) in a sterile solution for intravenous, intramuscular, intra-articular, or soft-tissue injection. Ophthalmic, otic, and topical formulations contain dexamethasone or dexamethasone sodium phosphate at concentrations appropriate for local use. Strength and exact excipients vary by manufacturer and formulation; refer to the specific product label for details.

Roxadex is a synthetic, fluorinated glucocorticoid that is one of the most potent corticosteroids in clinical use, with anti-inflammatory potency roughly 25-30 times that of hydrocortisone and essentially negligible mineralocorticoid (sodium/water-retaining) activity. It has a long biological half-life, allowing once-daily or intermittent dosing for many indications. Roxadex is available as oral tablets and oral solution, injectable solution for intravenous, intramuscular, or local (intra-articular/intralesional) use, and as ophthalmic, otic, and topical preparations.

Roxadex belongs to the class of corticosteroids (glucocorticoids), specifically the synthetic long-acting glucocorticoid subclass, used systemically and topically for anti-inflammatory and immunosuppressive effect.

Dexamethasone binds to the intracellular glucocorticoid receptor, and the activated receptor-drug complex translocates to the cell nucleus, where it binds to glucocorticoid response elements on DNA to modulate gene transcription. This suppresses the expression of pro-inflammatory mediators (cytokines, prostaglandins, leukotrienes) and induces anti-inflammatory proteins such as lipocortin-1 (annexin A1), which inhibits phospholipase A2 and reduces arachidonic acid release.

Pharmacologic effects include suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability, suppression of the immune system, and reduction of inflammation in virtually any tissue. Dexamethasone has essentially no mineralocorticoid activity at clinical doses, distinguishing it from hydrocortisone.

Pharmacokinetics: Well absorbed orally with peak plasma concentration in 1-2 hours; plasma half-life is approximately 3-4.5 hours, but the biological (tissue) half-life of anti-inflammatory action is much longer, approximately 36-54 hours, allowing once-daily or alternate-day dosing. It is metabolized in the liver (primarily via CYP3A4) and excreted mainly in urine. Dexamethasone crosses the placenta and is present in breast milk.

Roxadex tablets/oral solution may be taken with or after food to reduce gastrointestinal irritation. Do not crush or chew extended-release preparations if prescribed as such (most tablets are immediate-release). Injectable Roxadex is administered by a healthcare professional via intravenous, intramuscular, intra-articular, intralesional, or soft-tissue routes, depending on formulation and indication. Ophthalmic and otic drops should be used exactly as directed, avoiding contamination of the dropper tip. When discontinuing after prolonged use, the dose must be tapered gradually rather than stopped abruptly (see Precautions and Warnings).

Only well-established, clinically significant interactions with Roxadex are listed below.

• CYP3A4 inducers (e.g. phenytoin, rifampin, carbamazepine, phenobarbital) — may increase the metabolic clearance of Roxadex, reducing its effectiveness; dose adjustment may be needed.
• CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, clarithromycin) — may reduce clearance and increase Roxadex levels/effect, increasing risk of corticosteroid side effects.
• NSAIDs and aspirin — concurrent use with Roxadex increases the risk of gastrointestinal ulceration and bleeding.
• Anticoagulants (e.g. warfarin) — Roxadex may alter anticoagulant response (usually decreasing effect); coagulation status should be monitored more closely.
• Antidiabetic agents (insulin, oral hypoglycemics) — Roxadex raises blood glucose and may reduce the effectiveness of these medicines; dose adjustment may be required.
• Live or live-attenuated vaccines — should not be given to patients on immunosuppressive doses of Roxadex due to risk of disseminated vaccine-strain infection and reduced antibody response.
• Potassium-depleting diuretics (e.g. furosemide, thiazides) — combined use with Roxadex increases the risk of hypokalemia.

Side effects of Roxadex are generally related to dose and duration of therapy.

Common

• Increased appetite, weight gain, fluid retention
• Insomnia, mood changes, nervousness or restlessness
• Indigestion, nausea
• Elevated blood glucose
• Acne, skin thinning, easy bruising

Less common but significant

• Adrenal suppression (see Precautions and Warnings)
• Increased susceptibility to infection, masking of signs of infection
• Peptic ulceration, especially with concurrent NSAID use
• Osteoporosis and increased fracture risk with long-term use
• Cataracts, glaucoma (with prolonged use, especially ophthalmic)
• Growth suppression in children with prolonged use
• Psychiatric effects including mood swings, insomnia, and rarely psychosis (can occur even with short courses in susceptible individuals)
• Hypertension, hypokalemia
• Cushingoid features (moon face, central obesity) with prolonged use

Roxadex crosses the placenta. It should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician must be consulted before use in pregnancy. Roxadex is specifically used under specialist obstetric supervision in certain circumstances (e.g. to accelerate fetal lung maturation before anticipated preterm birth), where the benefit is considered to outweigh the risk in that specific clinical context; this does not imply general safety in pregnancy for other indications.

Roxadex passes into breast milk. Breastfeeding mothers should use it only under medical advice, weighing the benefit of treatment against potential effects on the infant, particularly with prolonged or high-dose therapy.

Adrenal suppression: Prolonged or high-dose use of Roxadex can suppress the hypothalamic-pituitary-adrenal (HPA) axis. Do not stop abruptly after extended use; the dose must be tapered gradually under medical supervision to avoid acute adrenal insufficiency, especially during stress, surgery, or illness.

Infection risk: Roxadex can suppress the immune system and mask signs and symptoms of infection, and may permit new infections to appear. Use with caution in patients with active or latent tuberculosis, systemic infections not controlled by anti-infective therapy, or recent live vaccine administration.

Metabolic effects: May cause or worsen hyperglycemia; blood glucose should be monitored, particularly in patients with diabetes or risk factors for it.

Musculoskeletal: Long-term use is associated with osteoporosis and increased fracture risk; calcium/vitamin D supplementation and bone density monitoring may be advised for prolonged therapy.

Growth: In children, prolonged use of Roxadex may suppress growth; growth and development should be monitored during extended therapy.

Psychiatric effects: Mood changes, insomnia, and rarely severe psychiatric reactions including psychosis can occur, even with short courses, particularly in patients with a history of mood or psychiatric disorders.

Gastrointestinal: Increased risk of peptic ulceration, especially when combined with NSAIDs; use with caution in patients with a history of peptic ulcer disease.

Ocular: Prolonged use may cause cataracts, glaucoma, or secondary ocular infections; periodic eye examinations are recommended with long-term therapy.

Cardiovascular/renal: Use with caution in patients with hypertension, congestive heart failure, or renal impairment, as fluid retention and electrolyte disturbances (e.g. hypokalemia) may occur.

Acute overdose of Roxadex is unlikely to cause life-threatening effects, but repeated or excessive dosing can worsen known corticosteroid side effects (e.g. fluid retention, hyperglycemia, hypertension, mood disturbance). There is no specific antidote. If overdose is suspected, seek immediate medical attention or contact a poison control center; treatment is supportive and symptomatic, with dose reduction or tapering as directed by a physician. Do not attempt to manage a suspected overdose at home without medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not use after the expiry date printed on the pack. Injectable formulations should not be used if the solution is discolored or contains particulate matter.

Elderly: May be at greater risk of osteoporosis, hypertension, hypokalemia, diabetes, susceptibility to infection, and skin thinning/fragility with Roxadex; use the lowest effective dose with close monitoring.

Hepatic impairment: Metabolism of Roxadex occurs primarily in the liver; use with caution and monitor closely in patients with significant hepatic impairment, as clearance may be reduced.

Renal impairment: No well-established fixed dose adjustment is required, but fluid and electrolyte status should be monitored, particularly in patients with significant renal impairment.

Diabetes mellitus: Roxadex can raise blood glucose; closer monitoring and adjustment of antidiabetic therapy may be needed.

See Pediatric Uses and Pregnancy and Lactation for further population-specific guidance.

Duration of Roxadex therapy depends entirely on the condition being treated, ranging from a single dose (e.g. croup, antiemetic prophylaxis) to short courses of a few days (e.g. COVID-19, bacterial meningitis adjunct, cerebral edema) to longer-term maintenance therapy for chronic inflammatory or autoimmune conditions, which requires periodic physician review. Treatment beyond short courses should be tapered gradually rather than stopped abruptly; see Precautions and Warnings.

Dexamethasone is classified as a corticosteroid (glucocorticoid), specifically a synthetic, long-acting glucocorticoid with minimal mineralocorticoid activity.

Dexamethasone acts by binding to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription — suppressing pro-inflammatory cytokines, prostaglandins, and leukotrienes, and inducing anti-inflammatory mediators such as lipocortin-1. This results in broad anti-inflammatory and immunosuppressive effects with minimal mineralocorticoid (sodium/water-retaining) activity, distinguishing it from corticosteroids such as hydrocortisone.

Category C (FDA legacy pregnancy category)

Roxadex is used in children for specific approved and guideline-supported indications, including croup, adjunctive treatment of bacterial meningitis, certain allergic and inflammatory conditions, and as part of chemotherapy/antiemetic regimens, generally with weight-based dosing (see Dosage and Administration). Safety and efficacy for indications beyond these established uses have not been fully established in all pediatric age groups, and use should always be guided by a pediatrician.

Prolonged use in children carries a risk of growth suppression; growth and development should be monitored during extended therapy, and the lowest effective dose for the shortest duration should be used.